Why Arcus Biosciences, Inc.’s (RCUS) Stock Is Down 8.54%
As of Thursday, November 05, Arcus Biosciences, Inc.’s RCUS share price has dipped by 8.54%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Commentary & Analysis
Which Is a Better Investment, Arcus Biosciences, Inc. or Vir Biotechnology, Inc. Stock?
Learn more about whether Arcus Biosciences, Inc. or Vir Biotechnology, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Why Arcus Biosciences, Inc.’s (RCUS) Stock Is Down 10.53%
As of Wednesday, October 21, Arcus Biosciences, Inc.’s RCUS share price has dipped by 10.53%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Arcus Biosciences, Inc.’s (RCUS) Stock Is Down 11.49%
As of Wednesday, October 21, Arcus Biosciences, Inc.’s RCUS share price has dipped by 11.49%, which has investors questioning if this is right time to buy.Tudor Pop
Why Arcus Biosciences, Inc.’s (RCUS) Stock Is Up 9.51%
As of Tuesday, October 20, Arcus Biosciences, Inc.’s RCUS share price has surged by 9.51%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,547.2 | $214.3 | 58% |
|
| Shares Out (Mil) | 127.4 | 53.9 | 67% |
|
| Institutional Ownership | 95.3% | 92.9% | 67% |
|
| Float (Mil) | 107.0 | 41.4 | 62% |
|
| Beta | 1.09 | 0.96 | 65% |
|
| Avg Daily Volume (000s) | 2,390 | 506 | 83% |
|
| Price Change (52-week) |
(10.8%) | 43.9% | 41% |
|
| Growth | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 25.9% | 13.2% | 87% |
|
| Net Income (5yr) | (23.5%) | (10.1%) | 17% |
|
| EPS (5yr) | (7.9%) | 15.8% | 23 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (20.6%) | (15.7%) | 32% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($0.893) | ($3.516) | ($3.123) | |
| Month Ago EPS | ($0.864) | ($3.480) | ($3.266) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.913) | ($3.648) | ($3.253) | |
| Year/Year Chg | (11.1%) | 7.0% | (11.8%) | |
| Financials | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $100 | $37 | 26% |
|
| Net Income (TTM) (Mil) | ($453) | ($44) | 3% |
|
| EPS (TTM) | ($3.643) | ($1.500) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($465) | ($34) | 2% |
|
| Net Cash Flow (TTM) (Mil) | ($87) | $1 | 16% |
|
| Long-Term Debt (Q1) (Mil) | $227 | $4 | 51% |
|
| Enterprise Value (Q1) (Mil) | $2,184 | $172 | 50% |
|
| Valuation | RCUS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.30 | 2.00 | 85% |
|
| P/E | na | 18.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (373.0%) | 67.3% | 1% |
|
| Net Margin | (453.0%) | (63.5%) | 2% |
|
| ROA | (50.6%) | (47.5%) | 11% |
|
| ROE | (114.1%) | (53.3%) | 8% |
|
| Liabilities to Assets | 56.2% | 29.6% | 49% |
|
| F-Score | 1 | 2 | na |
|
Arcus Biosciences, Inc. did not pass any screens on 11/5/2026.
